Management team
CEO Antti Vuolanto, DSc (Tech), started in his current role in July 2022. He joined Herantis Pharma Plc in February 2018 as COO. Antti has vast experience in financing, partnering, research, development, and manufacturing of biological drugs. Previously he served as COO at Valo Therapeutics, Executive Vice President at Targovax ASA, and COO and co-founder at Oncos Therapeutics Ltd that merged with Targovax in 2015. Dr. Vuolanto graduated as Doctor in Science in Technology at Aalto University, Finland, in 2004 in bioprocess engineering.
CFO Tone Kvåle joined Herantis as CFO in October 2020. She has 30 years of experience from the biotech, medtech and life sciences industry. She held CFO roles at Nordic Nanovector (publicly listed company), NorDiag (publicly listed company), Kavli Holding, Dynal Biotech, as well as senior management positions at Invitrogen/Life Technologies, in US, now part of Thermo Fisher. She is member of board and audit committee chair of MedinCell (MEDCL), France, member and chair of audit committee of Lifecare ASA, Norway and has been board member and chair of the audit committee of Bonesupport AB (BONEX), Sweden from December 2016 until May 2022. Tone has a diploma in finance and administration from UiT, The Arctic University of Norway, Harstad. She has completed the prescribed course of study and the examination for Advanced Programme in Corporate Finance at The Norwegian School of Economics, NHH.
CSO Henri Huttunen co-founded Herantis Pharma Plc. in 2008 and served as the company’s founding CEO for the first two years. Dr. Huttunen is currently the Chief Scientific Officer of Herantis. Dr. Huttunen has previously held research positions at the University of Helsinki, Orion Pharma, and Massachusetts General Hospital, Harvard Medical School (USA). Dr. Huttunen has a PhD in biochemistry from the University of Helsinki and 25 years of experience in neuroscience research. As an adjunct professor, Dr. Huttunen previously lead an academic research group focusing on molecular mechanisms of neurodegenerative diseases at the Neuroscience Center, University of Helsinki.
CMO Juha Savola, MD, PhD, joined Herantis in June 2026. He brings more than 25 years of experience in drug development, regulatory affairs and executive leadership across neurology, gene therapy and rare diseases. Most recently, he served as Vice President, Clinical Development at Spark Therapeutics (Philadelphia, USA), where he led clinical programmes spanning ophthalmology and neurology, including Huntington’s disease, Parkinson’s disease and epilepsy. Prior to Spark, he held senior leadership positions at Teva Pharmaceuticals, F. Hoffmann-La Roche, Santhera Pharmaceuticals and Juvantia Pharma, contributing to global development strategies across the US, Europe and Asia. In addition to his industry experience, Juha is a physician-scientist with an MD and PhD from the University of Oulu. He has held academic appointments including Associate Professor at the University of Turku, and has authored more than 70 peer-reviewed publications covering neurodegenerative diseases, receptor pharmacology, clinical development and gene therapy.